PDBsum entry 2kh2

Cytokine/immune system

PDB id: 2kh2

Contents

Protein chains

153 a.a. *

254 a.a. *

* Residue conservation analysis

PDB id:

2kh2

Name:

Cytokine/immune system

Title:

Solution structure of a scfv-il-1b complex

Structure:

Interleukin-1 beta. Chain: a. Synonym: il-1 beta, catabolin. Engineered: yes. Scfv. Chain: b. Engineered: yes

Source:

Homo sapiens. Human. Organism_taxid: 9606. Gene: il1b, il1f2. Expressed in: escherichia coli. Expression_system_taxid: 562. Mus musculus. Mouse. Organism_taxid: 10090.

NMR struc:

77 models

Authors:

I.C.Wilkinson,C.J.Hall,V.Veverka,F.W.Muskett,P.E.Stephens,R.J.Taylor, A.J.Henry,M.D.Carr

Key ref:

I.C.Wilkinson et al. (2009). High resolution NMR-based model for the structure of a scFv-IL-1beta complex: potential for NMR as a key tool in therapeutic antibody design and development. J Biol Chem, 284, 31928-31935. PubMed id: 19776018

Date:

23-Mar-09 Release date: 08-Sep-09

Protein chain

P01584  (IL1B_HUMAN) -  Interleukin-1 beta from Homo sapiens

Seq: 269 a.a.

Struc: 153 a.a.

Protein chain

No UniProt id for this chain

Struc: 254 a.a.

J Biol Chem 284:31928-31935 (2009)

PubMed id: 19776018

High resolution NMR-based model for the structure of a scFv-IL-1beta complex: potential for NMR as a key tool in therapeutic antibody design and development.

I.C.Wilkinson, C.J.Hall, V.Veverka, J.Y.Shi, F.W.Muskett, P.E.Stephens, R.J.Taylor, A.J.Henry, M.D.Carr.

ABSTRACT

Monoclonal antibodies have recently started to deliver on their promise as highly specific and active drugs; however, a more effective, knowledge-based approach to the selection, design, and optimization of potential therapeutic antibodies is currently limited by the surprising lack of detailed structural information for complexes formed with target proteins. Here we show that complexes formed with minimal antigen binding single chain variable fragments (scFv) reliably reflect all the features of the binding interface present in larger Fab fragments, which are commonly used as therapeutics, and report the development of a robust, reliable, and relatively rapid approach to the determination of high resolution models for scFv-target protein complexes. This NMR spectroscopy-based approach combines experimental determination of the interaction surfaces and relative orientations of the scFv and target protein, with NMR restraint-driven, semiflexible docking of the proteins to produce a reliable and highly informative model of the complex. Experience with scFvs and Fabs targeted at a number of secreted regulatory proteins suggests that the approach will be applicable to many therapeutic antibodies targeted at proteins, and its application is illustrated for a potential therapeutic antibody targeted at the cytokine IL-1beta. The detailed structural information that can be obtained by this approach has the potential to have a major impact on the rational design and development of an increasingly important class of biological pharmaceuticals.